CLINICAL_TRIALS
trial_result
· 2012-01-27
Clinical Trial Update: Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension [Phase 2]
Summary
This document reports results from a Phase 2 extension study of ambrisentan in pulmonary arterial hypertension, with results posted in January 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Pulmonary Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2012-01-27